Eris reports problems identified at Swiss Parenterals facilities; expected effect appears limited.

Eris Lifesciences Ltd announced on Monday, April 20, that Croatia’s medicines regulator HALMED has identified non-compliance issues following an inspection of its subsidiary Swiss Parenterals Ltd.’s manufacturing facilities in Ahmedabad, Gujarat.

The inspection took place from March 9 to 13, 2026, and included Unit 1, responsible for producing general liquid and dry powder injectables, and Unit 2, which manufactures betalactam dry powder injectables, as stated in an exchange filing.

The company confirmed that it has acknowledged the observations and will respond within the required timelines while taking necessary actions to regain approvals for both facilities, according to the filing.

Eris Lifesciences described the findings as procedural, requiring enhancements to align with Good Manufacturing Practice (GMP) standards under EU Directive (EU) 2017/1572.

The company intends to apply remediation measures, submit corrective and preventive actions (CAPAs), and request a follow-up inspection from the regulator.

Eris Lifesciences noted that the effect on its current business is projected to be minimal, although some delays in the commercialization of its EU-focused CDMO product pipeline may occur. The company reaffirmed its dedication to upholding high manufacturing standards and will provide updates to stock exchanges regarding future developments, as noted in the filing.

On Monday, April 20, shares of Eris Lifesciences Ltd closed slightly lower, down 0.91% at 1,432.40 on the NSE.